Important news! Moments ago I learned that the U.S. Supreme Court WILL hear our legal challenge to Myriad Genetics’ patents on the ”breast cancer genes,” BRCA 1 and 2! The Court will decide the essential question: Are human genes patentable?
We say “NO, they are not.”
Because Myriad owns the patent on the BRCA 1 and 2 genes, women are faced with a high cost for the BRCA genetic test (over $3,000) and have no options for second opinion testing. In addition, the corporate ownership of these human genes limits invaluable research needed to better understand breast cancer.
Our legal challenge to Myriad is important for women affected by breast cancer. And this is a groundbreaking case that has enormous national and international implications beyond breast cancer. As always, we will continue to work for the big, sweeping, system-wide changes that will benefit the health of all women. Thanks for being in it for the long haul with us.
Since 2009, Breast Cancer Action has been at the forefront of this legal challenge brought by the ACLU. We are the only national breast cancer organization represented as a plaintiff in this legal challenge against Myriad’s ownership of human genes. We’re able to take on work like challenging human gene patents because we don’t take a dime from corporations that profit from or contribute to breast cancer (including Myriad). Thank you for your generous support that makes our work possible.
We expect the case will be heard this spring and we will keep you posted on details as they become available.
P.S. We’re able to be fearless advocates for women’s health because of financial support from members like you. Can you chip in $10 or $20 today to fund our work challenging Myriad’s monopoly on the breast cancer genes?